Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2...
Major Depressive Disorder
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve...
Gilgamesh Pharmaceuticals, a clinical-stage neuroscience biotech developing best-in-class medicines to redefine mental healthcare, announces the successful completion...
Researchers at Fermata to Study SAINT Neuromodulation for Treatment-Resistant Major Depression
2 min read
Fermata, an outpatient psychiatric center of excellence, today announced a new clinical trial to study the SAINT™...
